Hepatocellular Carcinoma, Sarcopenia
Conditions
Keywords
hepatocellular carcinoma, sarcopenia, prognosis, adverse events, systemic therapy
Brief summary
Sarcopenia is associated with the prognosis of HCC and cholangiocarcinoma. But there has been rare study focusing on the effect of sarcopenia on the prognosis of HCC treated with systemic therapy, such as interventional therapy, targeted therapy, chemotherapy and immunotherapy and so on.
Detailed description
By tracking the short-term and long-term results of HCC patients treated with systemic therapy,the difference of short-term results between patients with sarcopenia and patients without sarcopenia was analyzed, and the correlation between sarcopenia and short-term and long-term results of patients after systemic treatments was explored, so as to improve people's awareness of sarcopenia and pay attention to its prevention and treatment.All implementation details are based on the newest EuropeanWorking Group on Sarcopenia in Older People(EWGSOP) definition. The investigators consecutively admitted patients the questionnaire and evaluated the assessment of muscle strength (grip strength test and chair stand test), muscle quantity (L3 plane total skeletal muscle area) and physical performance (gait test) following the F-A-C-S approach, to confirm patients with sarcopenia accurately. And by tracking the short-term and long-term outcomes, the differences were analyzed and the relationship between sarcopenia and prognosis of systemic treatments was explored.
Interventions
DIAGNOSTIC_TESTDiagnostic Test: gait speed; ct scan; grip strength and chair stand test
The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
Sponsors
The First Affiliated Hospital of Zhejiang Chinese Medical University
Eastern Hepatobiliary Surgery Hospital
Qilu Hospital of Shandong University
First Affiliated Hospital of Wenzhou Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* clinical diagnosis of hepatocellular carcinoma * No cancer other than liver cancer has been diagnosed * Age ≥18 years * child-pugh score≤7
Exclusion criteria
* uncompleted standard tests and questionnaires * received other therapies * Patients who had other causes of muscle weakness (injury, fracture, stroke, etc.) * Patients who missing CT data or CT scan did not reach the level of the third lumbar vertebra (L3) * lost follow-up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| complications | 3 months | The complications were classified according to the Clavien-Dindo classification, such as hypertension, fever, abdominal pain and so on. |
| overall survival | 2 years | Overall survival was defined as the time from initiation of lenvatinib to death for any reason. |
| progression free survival | 2 years | Progression free survival was defined as the time from initiation of lenvatinib to first progression or death. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospital stay | 3 months | The time that patients spent in the hospital was recorded. |
| Hospital cost | 3 months | Hospital cost that patients spent was recorded. |
Countries
China
Outcome results
None listed